Abstract: The present invention is directed to methods and apparatus for detection of one or more analytes. Analytes include agents or components of infectious agents such as pathogenic virus, as well as enzymes, proteins and biomarkers.
Type:
Application
Filed:
May 11, 2010
Publication date:
December 23, 2010
Applicant:
Nexus DX, Inc.
Inventors:
Richard Laswell Egan, Graham Peter Lidgard, David Dickson Booker, Christopher Johann Johnson, Alexander Belenky, Stan Vukajlovich, John Zeis, Scott Castanon
Abstract: A diagnostic assay system including a test device and a scanning device are described. In one implementation, the scanning device includes a source of electromagnetic radiation, an optics assembly, a detector, and a microprocessor disposed within a chassis. The test device and scanning device may be configured to be movable relative to each other during operation of the scanning device.
Type:
Application
Filed:
April 7, 2010
Publication date:
December 16, 2010
Applicant:
NEXUS DX, INC.
Inventors:
Richard Egan, Graham Lidgard, David Booker
Abstract: The invention describes methods for predicting outcome for patients suffering from traumatic brain injury (TBI) by evaluating levels of markers commonly associated with cellular damage in bodily fluids. Utilization of such methods improves diagnosis and treatment of patients suffering from traumatic brain injury, thus potentially minimizing and/or eliminating long-term adverse effects in these patients.
Type:
Application
Filed:
March 29, 2010
Publication date:
September 30, 2010
Applicant:
NEXUS DX, INC.
Inventors:
GEORGE JACKOWSKI, ERIC B. STANTON, PETRO KUPCHAK, MIYOKO TAKAHASHI, MICHELLE DAVEY
Abstract: The invention provides a method to efficiently express high levels of a recombinant untagged NT-proBNP for use as a calibrator in NT-proBNP immunoassays.
Type:
Grant
Filed:
February 4, 2003
Date of Patent:
August 3, 2010
Assignee:
Nexus DX, Inc.
Inventors:
Azhar Alvi, William Yajima, Roshana Sikora, George Jackowski, Mee-Ra Hong
Abstract: A method for determining whether a subject has had a stroke and, if so, the type of stroke which includes analyzing the subject's body fluid for at least four selected markers of stroke, namely, myelin basic protein, S100 protein, neuronal specific enolase and a brain endothelial membrane protein such as thrombomodulin or a similar molecule. The data obtained from the analyses provide information as to the type of stroke, the onset of occurrence and the extent of brain damage and allow a physician to determine quickly the type of treatment required by the subject.